Trial for targeted colorectal cancer treatment withdrawn before starting
NCT ID NCT07323576
Summary
This study was designed to test whether adding a new drug called inavolisib to standard chemotherapy could better control advanced colorectal cancer that has spread and has a specific genetic change (PIK3CA mutation). It was intended for people who had not yet received treatment for their metastatic cancer. The trial was withdrawn by the sponsor before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.